Kaletra and Viread in Antiretroviral Naïve Patients: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Kaletra and Viread in Antiretroviral Naïve Patients (NCT00679926), a na phase 4 study. The primary outcome is To Assess the Efficacy of Once Daily Antiretroviral Therapy With Viread 300mg and Kaletra 800mg/200mg in Suppressing HIV RNA Levels to <50 Copies/ml in Antiretroviral naïve Patients..

2. Clinical Question

This is a question about viral-load suppression during treatment, not a randomized comparison of the regimen with another treatment. The record also lists secondary questions about lower-threshold viral load, viral decline, CD4 counts, virologic failure, tolerability, adverse events, fasting lipids, and adherence measured with medication electronic monitoring system caps. Their presence identifies intended areas of assessment; it does not establish that data were collected or analyzed for them.

3. Trial Design

The registry describes a Phase IV, open-label, single-group investigation of once-daily antiretroviral therapy in antiretroviral-naïve patients with HIV infections. The intervention is a drug regimen combining Viread and Kaletra. The arm description specifies 4 lopinavir/ritonavir tablets at 200mg/50mg each and 1 tenofovir 300mg tablet, taken every 24 hours. The stated regimen corresponds to the once-daily study intervention; no separate control arm is listed.

Allocation is recorded as not applicable, masking as none, and the study model as single group. Thus, the registry does not describe random assignment or blinding. Without a concurrent comparator group, the intended study question concerns the regimen’s observed viral-load suppression over time rather than a between-group treatment effect. Changes during follow-up cannot be separated from other influences using a randomized comparison within this study design.

The registry lists enrollment as 6 and status as terminated. It gives a study start of 2008-05 and primary completion of 2011-05. The primary-outcome population description says the study was terminated due to lack of enrollment and that data were not collected from 13 out of 15 participants. These entries are inconsistent with the enrollment field, and the registry record does not explain their relationship. They should be read as separate statements in the record, not combined into an inferred participant flow.

The registry identifies the sponsor as Oklahoma State University Center for Health Sciences. It lists 12 outcome measures and no analysis entries. The protocol’s statistical analysis plan, sample-size justification, planned interim analyses, and rules for handling incomplete follow-up are not reported in the registry record. The listed dates and design details therefore describe the registry entry, but they do not establish what analyses were completed or what data were available.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: There are no significant events prior to enrollment. Patients had to be naive to HIV therapy prior to treatment drug.

Overall Study

Analysis population for the primary outcome, as defined in the registry: The study was terminated due to lack of enrollment and data were not collected from 13 out of 15 participants.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as To Assess the Efficacy of Once Daily Antiretroviral Therapy With Viread 300mg and Kaletra 800mg/200mg in Suppressing HIV RNA Levels to <50 Copies/ml in Antiretroviral naïve Patients., measured over 4, 8, 12, 16, 24, 32, 40, and 48 weeks.

The primary endpoint is intended to measure the proportion of patients whose plasma HIV-1 RNA is below <50 copies/ml at the end of 48 weeks of therapy. In general, a threshold-based viral-load endpoint classifies each assessed patient according to whether the measured value falls below the specified cutoff. The proportion then represents how often that endpoint was met among the patients included in the analysis. The registry record does not report the observed proportion, its denominator, or an estimate of uncertainty.

The registry also lists assessment time points at 4, 8, 12, 16, 24, 32, and 40 weeks, in addition to the 48-week endpoint. Repeated assessments can describe how viral load changes during follow-up and whether suppression is maintained, but they do not substitute for a reported primary endpoint result. The primary outcome description emphasizes the proportion at the end of 48 weeks.

In general, a threshold endpoint can be clinically interpretable because it expresses whether an individual measurement meets a defined viral-load criterion. Its interpretation depends on complete and consistently measured follow-up, a clear definition of the analysis population, and transparent handling of missing measurements. Those details are not reported in the registry record. The record’s statement that data were not collected from 13 out of 15 participants raises a substantial completeness concern, while the enrollment field reports 6. The record does not clarify how those entries relate to the intended endpoint denominator.

No primary endpoint result or sponsor analysis is reported in the registry record. Consequently, the endpoint’s intended meaning can be described, but the study’s observed suppression proportion and its precision cannot be assessed from the registry information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies a single-group study, but it does not report a statistical analysis plan. The statistical ideas below are general explanations of how study results are often assessed; they should not be read as methods confirmed for this trial. The record does not report a sponsor analysis, an endpoint estimate, or an uncertainty interval.

What does a single-group design estimate?

In general, a single-group study can describe outcomes among people who receive the intervention and have outcome data. For a threshold endpoint, that description would typically include the number meeting the threshold, the relevant analysis denominator, and the resulting proportion. A confidence interval can express how imprecisely that proportion is estimated, reflecting that a study’s observed participants are only one possible realization of the underlying process. Neither the observed proportion nor its confidence interval is reported in the registry record.

A single-group result is not a randomized contrast. Without a concurrent comparator, changes in the outcome cannot be attributed solely to the regimen by comparing treatment groups within the study. General influences such as the course of illness, other care, changes over time, and participant selection can also affect an observed outcome. The registry lists allocation as not applicable and the model as single group; a control arm is not reported.

Why does the endpoint definition matter?

The primary endpoint uses a viral-load threshold: HIV RNA below <50 copies/ml at the end of 48 weeks of therapy. In general, threshold endpoints turn a measurement into a category, such as meeting or not meeting a defined cutoff. This can make a result straightforward to describe, but the estimate depends on how the endpoint is measured and who is included in its denominator. A result among participants with recorded measurements may differ from a result that treats missing measurements in another way. The registry record does not specify the analysis denominator or missing-data rule.

The record also lists repeated assessment times and several secondary outcomes. In general, repeated measures can describe change across follow-up, while secondary outcomes can address related but distinct questions. A statistical analysis plan ordinarily clarifies which outcome is primary, how repeated measurements are modeled, and how secondary analyses are handled. Such a plan is not reported in the registry record. The listed outcomes alone do not reveal what analyses were conducted.

What is over-dispersion, and is it relevant?

In general, over-dispersion occurs when observed variation in count or proportion data exceeds what a chosen statistical model assumes. If ignored, uncertainty estimates can be too narrow. A suitable analysis may account for extra variation when the data structure and assumptions warrant it. The registry record does not report an outcome dataset, a statistical model, or an assessment of over-dispersion. This is therefore a general consideration, not a claim about an analysis performed in this study.

How should planning calculations be read?

In general, a sample-size illustration answers a hypothetical planning question under specified assumptions; it is not a summary of what the study observed, and it is not observed power. The registry’s planning assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a stated fraction of the observed effect. The assumptions also distinguish total events for time-to-event calculations from participants per arm for other calculations. Those two-arm planning assumptions do not describe the registry’s single-group trial design. The registry record does not report an observed effect estimate on which to base a substantive interpretation, and no calculated planning values are stated in the record information.

In general, a significance level is a threshold used in a testing procedure, while a confidence interval gives a range of values compatible with the data under the method’s assumptions. Neither quantity, by itself, establishes clinical importance or removes bias due to missing data or design limitations. No test result, p-value, or confidence interval is reported for this trial. Because the study’s endpoint results and analysis methods are not reported, numerical statistical interpretation is not possible from the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary endpoint and a set of secondary outcomes addressing viral-load thresholds, viral decline, CD4 counts, time to virologic failure, tolerability and adverse events, fasting lipids, and adherence. It also lists 12 outcome measures, while the analysis count is 0. The record does not report a multiplicity plan, such as whether secondary outcomes were intended to be confirmatory or exploratory, whether testing order was prespecified, or whether any adjustment for multiple comparisons was used. Without that information and without reported results, the chance of selectively emphasizing favorable findings cannot be assessed.

Missing data are a central concern. The primary-outcome population description states that the study was terminated due to lack of enrollment and that data were not collected from 13 out of 15 participants. The enrollment field separately reports 6, and the adverse-event group lists 15 at risk. The registry record does not reconcile these statements or explain which outcome measurements were available. It also does not report reasons for missing outcome data beyond lack of enrollment, the timing of missingness, or whether missingness differed across follow-up assessments.

In general, an analysis population specifies which participants contribute to an estimate, and a missing-data method explains how unavailable measurements are treated. Common approaches can make different assumptions and lead to different conclusions; the appropriate choice depends on the study and the missingness mechanism. The registry record does not report an analysis population, an imputation method, a sensitivity analysis, or a rule for handling participants without endpoint measurements. No analysis denominator or endpoint result is reported. These omissions prevent assessment of how incomplete follow-up affected any possible estimate.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry’s adverse-event entry describes a single treatment arm titled “Single Treatment Arm.” It lists 15 participants at risk for serious adverse events and 0 affected, and 15 at risk for other adverse events and 0 affected. The deaths field is null, which means a death count is not reported in the registry record; it should not be interpreted as a reported count of zero.

These figures are registry entries, not a complete safety assessment. The record does not provide event-level details, follow-up duration for safety, or an explanation of how the risk counts relate to the enrollment field of 6 and the primary-outcome statement referring to 15 participants. It also does not list top serious-event terms. The record does not clarify whether the zero affected counts reflect complete event ascertainment for all participants listed at risk.

In general, a reported zero indicates that no affected participants were recorded in that category under the registry’s reporting, but it does not by itself establish that no events occurred outside the recorded scope or that risk is absent. A safety count is most informative when its denominator, observation period, event definitions, and completeness are clear. Those details are not reported in the registry record. Because the study was terminated and participant information is inconsistent, the listed counts should be read narrowly as the adverse-event figures entered in the record, not as a comprehensive estimate of safety.

12. What the Result Does, and Does Not, Mean

The registry record establishes that the study was designed to examine once-daily Viread and Kaletra in antiretroviral-naïve patients with HIV, with suppression below <50 copies/ml at the end of 48 weeks as its primary objective. It also establishes that the study was open label, single group, and terminated. It does not report the primary endpoint result or a statistical analysis. No numerical conclusion about the proportion achieving suppression, the amount of change in viral load, or the precision of an effect estimate can be drawn from the registry information.

The record does not show that the regimen did or did not achieve its stated objective. A trial objective describes what investigators intended to evaluate; it is not a result. Likewise, the listed secondary outcomes are planned topics in the registry entry, not evidence that measurements were collected or that findings were analyzed. The absence of analysis entries does not establish whether analyses took place outside the registry, but the registry record does not report them.

The design also limits what a possible outcome could mean. In general, an uncontrolled single-group study can describe outcomes among assessed participants but cannot make a randomized comparison with another treatment. Open-label conduct means masking was not used, as recorded. The record does not report enough information to evaluate possible measurement or reporting influences, nor does it reconcile the participant-count statements or explain how missing data were handled.

The adverse-event entry records zero affected in both its serious and other adverse-event categories, with 15 at risk in each category. Those counts should not be converted into a broader claim about safety: the record’s enrollment and participant-data entries are inconsistent, and deaths are not reported. The figures are limited to the adverse-event fields recorded.

Thus, the appropriate interpretation is about the state of the registry evidence: the treatment question and intended outcomes are identifiable, but efficacy estimates and their uncertainty are not reported. The record’s design, termination, and incomplete or unreconciled participant information further constrain what can be inferred. A lack of reported results is not evidence for either benefit or lack of benefit.

13. Why This Trial Matters Statistically

This trial is statistically informative as an example of why design, enrollment, completeness, and reporting must be considered before interpreting an outcome. The registry states a clear threshold-based primary question, but does not report the primary result, an analysis, or an uncertainty estimate. Without those elements, the endpoint cannot be assessed quantitatively, regardless of how clearly the intended question is described.

The single-group, open-label design also frames the estimand: any reported outcome would describe the experience of assessed participants receiving the regimen, rather than a randomized difference from a comparator. That distinction is important when readers encounter a treatment objective or an observed change over time. A within-group observation is not equivalent to evidence from a controlled comparison.

The registry’s enrollment of 6 sits alongside a statement that data were not collected from 13 out of 15 participants and adverse-event risk counts of 15. This inconsistency makes participant accounting difficult and prevents a clear understanding of the denominator for either efficacy or safety. It demonstrates why participant flow and analysis-population definitions are essential parts of statistical reporting, not administrative details.

The record also lists multiple secondary outcomes without reporting an analysis plan or results. In general, when several outcomes are considered, readers need to know which analyses were prespecified and how multiplicity was handled. Here, those details are not reported in the registry record. The statistical significance threshold included in the planning assumptions does not substitute for an analysis plan or an observed result, and the two-arm planning assumptions do not match the listed single-group design.

The central statistical lesson is that a well-defined endpoint is not enough to support a conclusion. A usable interpretation also requires an analyzable dataset, clear denominators, transparent missing-data methods, and reported estimates with their uncertainty. The registry record documents the intended question but leaves those pieces unavailable or unresolved.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations restrict interpretation. The study is listed as terminated because of lack of enrollment, and the registry states that data were not collected from 13 out of 15 participants. The enrollment field reports 6, while the adverse-event entry lists 15 participants at risk. The registry record does not explain how these numbers relate, so participant flow and the endpoint denominator remain unclear.

No primary or secondary outcome results are reported in the registry record. Although the primary endpoint is described as the proportion below <50 copies/ml at the end of 48 weeks, the record does not provide a numerator, denominator, estimate, confidence interval, or statistical test. It is therefore not possible to assess the observed response or its precision. The registry also does not report how many participants reached each scheduled assessment time.

The single-group, open-label design has no concurrent randomized comparator. Any outcome description would not provide a randomized between-treatment contrast. The record does not report a statistical analysis plan, analysis population, missing-data strategy, multiplicity approach, or interim-analysis plan. These omissions prevent assessment of whether methods matched the intended endpoint and how incomplete data or multiple outcomes were handled.

Safety interpretation is also limited by the unreconciled at-risk count and enrollment entry. The adverse-event fields show 0 affected for serious events and 0 for other events, but the record does not clarify the completeness or duration of ascertainment. Deaths are not reported. Overall, the registry supports description of the intended study and its limitations, but not a reliable estimate of efficacy or a comprehensive safety conclusion.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Kaletra and Viread in Antiretroviral Naïve Patients — NCT00679926.
• Registry record last updated 2020-12-04; status last verified 2020-12.
• Results first posted 2020-12-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a Phase IV, open-label, single-group study of once-daily Viread and Kaletra in antiretroviral-naïve patients with HIV infections. The primary objective was to assess the proportion with HIV RNA below <50 copies/ml at the end of 48 weeks of therapy. The record lists enrollment of 6, a terminated status, and no masking or allocation to comparative arms.

The registry also states that termination was due to lack of enrollment and that data were not collected from 13 out of 15 participants. Its adverse-event entry lists 15 at risk and 0 affected for both serious and other adverse events; deaths are not reported. The enrollment and participant-data statements are not reconciled.

No efficacy results, statistical analysis, or analysis-population details are reported in the registry record. The intended question is clear, but the available information does not support a numerical conclusion about the primary endpoint or a comprehensive safety interpretation.